Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab + capecitabine in elderly patients with metastatic breast cancer
2009-016062-82Phase 2Terminated
- Sponsor
- South Eastern European Research Oncology Group
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and capecitabine in breast cancer, sponsored by South Eastern European Research Oncology Group. Primary endpoint: Treatment duration until disease progression or discontinuation. Started Oct 2009; status: terminated.
02
Drugs
bevacizumabcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-016062-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016062-82.